Verici Dx (VRCI) H2 2025 TU earnings summary

Executive summary

• Achieved strong growth in FY25 with significant commercial progress and increased adoption of Tutivia test.

• Secured Medicare coverage for Tutivia, expanding patient access and coverage to 68% of US transplant tests.

• Signed key agreements with Prime Health Services and Blue Cross Blue Shield of Illinois, enhancing network reach.

Financial highlights

• Total unaudited revenues reached $3.8m for FY25, up from $3.3m in 2024.

• Recognised revenue from Tutivia was $3.0m (2024: $0), with $3.2m in test orders.

• License income was $0.8m, down from $3.3m in 2024, reflecting milestone payment timing.

• Year-end unaudited cash stood at $3.3m (2024: $4.1m), slightly ahead of expectations.

• Accounts receivable at year-end was $1.6m (2024: $0), supporting cash runway into H2 2026.

Outlook and guidance

• Continued strong testing volume acceleration expected beyond the $3.2m of orders received in FY25.

• Confident in ongoing commercial traction and growth into 2026 and beyond.